MX359263B - Composiciones y métodos para el tratamiento de adicciones, trastornos psiquiátricos , y enfermedades neurodegenerativas. - Google Patents

Composiciones y métodos para el tratamiento de adicciones, trastornos psiquiátricos , y enfermedades neurodegenerativas.

Info

Publication number
MX359263B
MX359263B MX2012014846A MX2012014846A MX359263B MX 359263 B MX359263 B MX 359263B MX 2012014846 A MX2012014846 A MX 2012014846A MX 2012014846 A MX2012014846 A MX 2012014846A MX 359263 B MX359263 B MX 359263B
Authority
MX
Mexico
Prior art keywords
compositions
formulated
addiction
blood
treatment
Prior art date
Application number
MX2012014846A
Other languages
English (en)
Other versions
MX2012014846A (es
Inventor
E Goeders Nicholas
S Fox Barbara
Guerin Glenn
Original Assignee
Board Of Supervisors Of Louisiana State Univ & Agricultural & Mechanical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Supervisors Of Louisiana State Univ & Agricultural & Mechanical College filed Critical Board Of Supervisors Of Louisiana State Univ & Agricultural & Mechanical College
Publication of MX2012014846A publication Critical patent/MX2012014846A/es
Publication of MX359263B publication Critical patent/MX359263B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/043—Kallidins; Bradykinins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención ofrece, entre otras cosas, las composiciones farmacéuticamente aceptables que incluyen metirapol como el único agente farmacéuticamente activo; las composiciones que incluyen el metirapol y por lo menos un agente farmacéuticamente activo adicional; las composiciones en las cuales el agente que se dirige al eje HPA es, en sí, nuevo o modificado (por ejemplo, un anticuerpo biespecífico diseñado para atravesar la barrera hematoencefálica o un compuesto conocido rediseñado, por ejemplo, por la conjugación con una sustancia que atraviesa la barrera hematoencefálica); y las composiciones en las cuales el agente que se dirige al eje HPA se formula recientemente de una manera tal que no pueda inhibir significativamente la producción de cortisol en la glándula suprarrenal. Por ejemplo, la composición se puede formular para incluir una dosificación que es demasiado baja para reducir los niveles de cortisol en el plasma o se puede formular para preferiblemente afectar la piel.
MX2012014846A 2010-06-16 2011-06-16 Composiciones y métodos para el tratamiento de adicciones, trastornos psiquiátricos , y enfermedades neurodegenerativas. MX359263B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35548210P 2010-06-16 2010-06-16
PCT/US2011/040647 WO2011159871A2 (en) 2010-06-16 2011-06-16 Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease

Publications (2)

Publication Number Publication Date
MX2012014846A MX2012014846A (es) 2013-12-16
MX359263B true MX359263B (es) 2018-09-20

Family

ID=45348860

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012014846A MX359263B (es) 2010-06-16 2011-06-16 Composiciones y métodos para el tratamiento de adicciones, trastornos psiquiátricos , y enfermedades neurodegenerativas.

Country Status (11)

Country Link
US (2) US9078886B2 (es)
EP (1) EP2582375A4 (es)
JP (3) JP2013528658A (es)
KR (1) KR20130135820A (es)
CN (2) CN107625769A (es)
AU (2) AU2011268303A1 (es)
BR (1) BR112012032076A2 (es)
CA (1) CA2802957A1 (es)
MX (1) MX359263B (es)
RU (1) RU2674259C2 (es)
WO (1) WO2011159871A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006311458C1 (en) 2005-11-10 2013-05-09 Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College Compositions and methods for the treatment of addiction and other neuropsychiatric disorders
JP2013528658A (ja) 2010-06-16 2013-07-11 エンベラ ニューロセラピューティクス，インコーポレイティド 依存、精神疾患、及び神経変性病の治療のための組成物と方法
EP3107569A4 (en) 2014-02-20 2018-02-21 Alder Biopharmaceuticals, Inc. Anti-acth antibodies and use thereof
US20180185375A1 (en) * 2015-06-22 2018-07-05 Embera Neurotherapeutics, Inc. Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders
CA3014876A1 (en) * 2016-02-16 2017-08-24 Embera Neurotherapeutics, Inc. Compositions and methods for treating substance abuse disorders
CN109069515A (zh) * 2016-03-04 2018-12-21 安比拉神经疗法公司 用于治疗成瘾或物质使用障碍的组合物和方法
WO2018165649A1 (en) * 2017-03-10 2018-09-13 Embera Neurotherapeutics, Inc. Pharmaceutical compositions and uses thereof
US20200360400A1 (en) * 2017-05-19 2020-11-19 Embera Neurotherapeutics, Inc. Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease
KR102081177B1 (ko) 2017-12-12 2020-04-28 부산대학교 산학협력단 혈관-뇌장벽(Blood-brain barrier) 투과성을 증진시키는 W/O/W형 트리올레인 에멀전을 이용한 약물 전달 플랫폼
EP3840742B1 (en) * 2018-08-08 2024-04-24 Laviolette, Steven Robert L-theanine against thc-induced effects
CN109125338A (zh) * 2018-08-30 2019-01-04 泓博元生命科技（深圳）有限公司 一种促进神经系统修复的组合物及其制备方法与应用
CN109350734A (zh) * 2018-08-30 2019-02-19 泓博元生命科技（深圳）有限公司 促进神经系统修复的组合物及其制备方法与应用
CN120678950A (zh) * 2019-01-08 2025-09-23 乔治亚大学研究基金公司 靶向纳米颗粒以及它们的与真菌感染有关的用途
JP2023531735A (ja) * 2020-06-26 2023-07-25 デュレクト コーポレーション インスリン抵抗性、糖尿病、及び前糖尿病の少なくとも１つを処置するための酸素化コレステロールスルフェート類の使用
CN116059364B (zh) * 2021-11-04 2025-07-11 上海健康医学院 Dhcr7下调剂在减弱酒精诱导的肝脏肿瘤中的应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942162A (en) 1982-03-31 1990-07-17 University Of Tennessee Research Corporation Topical treatment of seborrheic dermatitis with ketoconazole
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US4594329A (en) 1984-05-14 1986-06-10 The Salk Institute For Biological Studies CRF analogs
US4661493A (en) 1985-03-29 1987-04-28 Pfizer Inc. Tioconazole and related compounds for control of Herpes simplex virus
US5016655A (en) 1986-10-21 1991-05-21 C.A. Blockers, Inc. Cigarette manufacturing process
US4814333A (en) 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
US4925844A (en) 1988-02-09 1990-05-15 Ici Americas Inc. Antagonizing the pharmacological effects of a benzodiazepine receptor agonist
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
DE3842007A1 (de) 1988-12-14 1990-06-21 Henkel Kgaa Fluessiges bis pastoeses, bleichmittelhaltiges waschmittel
US4974729A (en) 1989-04-17 1990-12-04 Bristol-Myers Squibb Company Reminder system for taking medication
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US20050090553A1 (en) * 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US6323312B1 (en) 1994-12-12 2001-11-27 The Salk Institute For Biological Studies Cyclic CRF antagonist peptides
US6326463B1 (en) 1994-12-12 2001-12-04 The Salk Institute For Biological Studies Cyclic CRF agonists
US20030211157A1 (en) 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US5869474A (en) * 1997-05-16 1999-02-09 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Low dosage treatment for cocaine craving and withdrawal
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
NZ334627A (en) 1999-03-12 2002-07-26 Horticulture & Food Res Inst A therapeutic composition containing a therapeutic agent such as an anthelmintic and an antistress agent such as metyrapone or a nitric oxide promoter for increasing efficacy of therapeutic agents and animal growth
GB0001449D0 (en) 2000-01-21 2000-03-08 Cortendo Ab Compositions
US6630449B2 (en) 2000-12-21 2003-10-07 David Wastchak Method for reducing the effect of nicotine addiction and dependancy
CA2452123A1 (en) 2001-06-26 2003-03-01 North Carolina State University Blocking peptide for inflammatory cell secretion
EP1523310A2 (en) 2002-07-09 2005-04-20 The Scripps Research Institute Method to inhibit ischemia and reperfusion injury
KR100503889B1 (ko) * 2002-07-20 2005-07-26 한국과학기술연구원 옥틸로늄 브로마이드를 함유하는 항암제 흡수 증진제
EP1551393A4 (en) 2002-07-30 2010-06-16 Peter Migaly COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS
US20040067986A1 (en) 2002-10-04 2004-04-08 Nathan Sassover Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer
US20050037983A1 (en) * 2003-03-11 2005-02-17 Timothy Dinan Compositions and methods for the treatment of depression and other affective disorders
US20080206138A1 (en) 2003-08-06 2008-08-28 Ilse Zolle Radiolabelled Phenylethyl Imidazole Carboxylic Acid Ester Derivatives
MXPA06002618A (es) 2003-09-09 2006-06-05 Ono Pharmaceutical Co Antagonistas del factor de liberacion de corticotropina (crf) y compuestos heterobiciclicos.
US20050203130A1 (en) 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
WO2005061508A1 (ja) 2003-12-22 2005-07-07 Ono Pharmaceutical Co., Ltd. 三環式複素環化合物およびその化合物を有効成分とする医薬
JP4399593B2 (ja) 2004-04-01 2010-01-20 国立大学法人 千葉大学 インフルエンザ脳症の検査法、及び、ヒト髄液中に発現するタンパク質からなるマーカ、診断薬、診断キット
AU2006311458C1 (en) 2005-11-10 2013-05-09 Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College Compositions and methods for the treatment of addiction and other neuropsychiatric disorders
CA2643802A1 (en) 2006-02-27 2007-09-07 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20080152709A1 (en) 2006-12-22 2008-06-26 Drugtech Corporation Clonidine composition and method of use
WO2009035473A2 (en) 2007-09-13 2009-03-19 Sanfilippo Louis C Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
WO2011064769A1 (en) 2009-11-24 2011-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and pharmaceutical compositions for the treatment of hot flashes
AU2011205290C1 (en) 2010-01-14 2014-11-06 Recordati Ag Use of an adrenal hormone-modifying agent
JP2013528658A (ja) 2010-06-16 2013-07-11 エンベラ ニューロセラピューティクス，インコーポレイティド 依存、精神疾患、及び神経変性病の治療のための組成物と方法
US20120237482A1 (en) 2011-03-18 2012-09-20 Juan Rodriguez Methods for treatment of neurological disorders by modulation of microglial activation
US20150278438A1 (en) 2012-04-23 2015-10-01 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Genetic predictors of response to treatment with crhr1 antagonists
EP2961390A1 (en) 2013-03-01 2016-01-06 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical formulations comprising quetiapine and escitalopram
KR20160026897A (ko) 2013-06-27 2016-03-09 세다르스-신나이 메디칼 센터 신경퇴행성 질환의 예방 및 치료를 위한 아드레날린 수용체 길항제
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use

Also Published As

Publication number Publication date
CN103037864A (zh) 2013-04-10
WO2011159871A2 (en) 2011-12-22
JP2016204394A (ja) 2016-12-08
BR112012032076A2 (pt) 2016-09-13
CN107625769A (zh) 2018-01-26
EP2582375A2 (en) 2013-04-24
AU2011268303A1 (en) 2013-01-24
MX2012014846A (es) 2013-12-16
JP2018188485A (ja) 2018-11-29
CA2802957A1 (en) 2011-12-22
AU2016262733A1 (en) 2016-12-15
US20160038509A1 (en) 2016-02-11
EP2582375A4 (en) 2013-12-25
US9987286B2 (en) 2018-06-05
RU2674259C2 (ru) 2018-12-06
US9078886B2 (en) 2015-07-14
JP2013528658A (ja) 2013-07-11
WO2011159871A8 (en) 2013-01-31
KR20130135820A (ko) 2013-12-11
WO2011159871A3 (en) 2012-04-19
US20130303523A1 (en) 2013-11-14
RU2013101766A (ru) 2014-07-27

Similar Documents

Publication Publication Date Title
MX2012014846A (es) Composiciones y metodos para el tratamiento de adicciones transtornos psiquiatricos , y enfermedades neurodegenerativas.
IN2015DN02829A (es)
PH12014501695B1 (en) Pde9 inhibitors with imidazo triazinone backbone
MX2020010151A (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn.
EP4592275A3 (en) Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
PH12017501294A1 (en) Compounds, compositions and methods useful for cholesterol mobilisation
TN2012000271A1 (en) Heteroaromatic phenylimidazole derivatives as pde10a enzyme inhibitors
MY158202A (en) 2-arylimidazole derivatives as pde10a anzyme inhibitors
MX2015008975A (es) Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn).
MD20140059A2 (en) Substituted 4-phenyl-pyridines for the treatment of NK-1 receptor related diseases
MY163327A (en) Imidazole derivatives as pde10a enzyme inhibitors
PH12018500030B1 (en) FORMULATIONS FOR ANTI-a4ß7 ANTIBODY
BR112014002202A2 (pt) macrociclos como inibidores de fator xia
TN2014000030A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
GEP20166450B (en) Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same
EP2542085A4 (en) COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDER
NZ702684A (en) Hexadepsipeptide analogues as anticancer compounds
MX336915B (es) Derivados de imidazol como inhibidores de la enzima pde10a.
TN2013000200A1 (en) Imidazole derivatives as pde 10a enzyme inhibitors

Legal Events

Date Code Title Description
FG Grant or registration